Update: Melanoma Focus appeal against the NICE Final Draft Guidance on Tebentafusp

On Friday 20 October 2023, Melanoma Focus along with Immunocore and OcuMelUK appealed against the negative NICE Final Draft Guidance on Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]. On 12 December 2023 NICE has announced that the appeal panel have upheld the appeal. This is great news for patients as the appraisal committee will now need to address the points set out in the decision letter.

This is an important step and means that the NICE appraisal committee will need to reassess tebentafusp.  We are awaiting to hear details regarding the date of the next NICE committee meeting.

You can find out more about the appeal update, here.

We also have information on our website about Tebentafusp, which you can access here.